Management Team

Icarus Consultants was founded in June 2004. We are a management consulting company that works with many of the world’s top pharmaceutical companies, leading biotechnology companies, and healthcare & life science companies in the United States (East Coast & West Coast), Canada & Europe.

Our services include:

The company senior management has over forty years of industry experience and multiple academic degrees in science, business and law.

This combination of clinical research, scientific, consulting and marketing experience provides the intellectual power to lead client engagements. The company also has a global network of consultants who are brought into projects, as required, based on their specialist expertise and staffing needs.

Sally Church, PhD

Sally Church 150x150 Management TeamBackground: 20 years of industry experience. Former Associate Director at Novartis Oncology; took Gleevec through phase I new product development to phase IV and three oncology launches in US market. Prior to that worked at Novartis & Sandoz in the UK as National Sales Manager, Product Manager. Spent over 4 years in key account, commercial, hospital and community sales. Twice Business Manager of the Year. Also worked in strategic planning dept.

Education:

  • PhD Kings College London, University of London
  • MSc Human & Applied Physiology, Kings College London, University of London
  • MBA Rutgers, State University of New Jersey
  • BSc(Hons) John Moores University, LIverpool
  • Executive Education in Finance, Harvard Business School

Expertise: Marketing Strategy, New Product Development, Pathway Evaluations, Licensing Analysis, Landscape Opportunity Assessments, Commercial Development Strategy, KOL Market Research, KOL Relationship Development, Qualitative Market Research, Competitive Intelligence, CI, Marketing Intelligence, Conference Coverage, Product Profiles, Pricing, Forecasting, Pharma PR & Social Media.

Therapeutic areas:  Oncology, Hematology, Immunology, Respiratory, Infectious Diseases, Wound Healing, Dermatology, Biosimilars, Stem Cell Therapy, Targeted Therapies

Professional Membership:

  • National Association of Science Writers (NASW)
  • Association of Health Care Journalists (AHCJ)
  • The New York Academy of Sciences (NYAS)
  • American Association for the Advancement of Science (AAAS)

In addition to her work at Icarus Consultants, Sally writes the Pharma Strategy Blog, a leading research orientated blog that provides commentary and insight on Pharma & Biotech new product development with an emphasis on oncology and hematology.

Pharma Strategy Blog was named by Ogilvy PR as one of the top pharma blogs to read in 2011.  To mark the writing of 900 blog posts, Sally produced a short video on why she blogs and what she writes about?

Additional information on Sally’s interests can be found in the about section of her blog. Sally has appeared on CNBC to talk about FDA Social Media policies and is regarded as one of the Top 50 women on Twitter.

Since March 2011, Sally has started producing video blogs about major medical meetings and scientific congresses she attends. Recent videos discuss research presented at EAU, AUA, EHA, AACR and ASCO.

As part of her “Making a Difference” series on Pharma Strategy Blog, at the September 2011 European Multidisciplinary Cancer Congress (ESMO/ECCO 2011) Sally interviewed Dr Gordon B. Mills MD PhD of the MD Anderson Cancer Center about personalized medicine and cancer drug development strategy:

Recently, Sally did a video preview of the 2011 San Antonio Breast Cancer Symposium (SABCS) and some of the exciting data expected at the meeting.

 

Pieter Droppert

PMD Pers Twitter picture 150x150 Management TeamBackground: 20 years of industry experience, starting as a CRA at Alcon on European clinical trials for intra-ocular lenses. Lead CRA & Project Manager of a European phase III IND program in Osteoporosis at Quintiles. Global Project Director for phase II Alzheimer’s program in emerging markets at CroMedica. Strategy consultant with Booz Allen Hamilton (now Booz & Co.), and VP Operations of a medical education company.

Education:

  • JD Rutgers School of Law, Newark NJ
  • MSc Management, Sloan Fellow, London Business School, University of London
  • MSc Human & Applied Physiology, Kings College London, University of London
  • MSc Cranfield University
  • BSc (Hons) The University of Sheffield
  • CDipAF Certified Diploma in Accounting & Finance (ACCA)

Expertise:  Marketing Strategy, Market Opportunity Assessments, Business & Market Intelligence, Market Research, Market Segmentation, Product Positioning, Corporate Growth Strategy, Emerging Markets, Clinical Research, Healthcare Regulatory Environment, Project Management.

Therapeutic areas: Ophthalmology, Respiratory, Anesthesiology, Alzheimers, Osteoporosis, Tissue Engineering, Med Devices, Biomarkers, Medical Imaging

Pieter is licensed to practice law in New Jersey, and is the legal counsel for Icarus Consultants.  In addition to his work at Icarus Consultants, Pieter writes the Biotech Strategy Blog on science, innovation and new product development.

He also undertakes freelance writing assignments and is developing skills in multimedia. The following video was the result of a 5 day digital media boot camp Pieter participated in at Columbia School of Journalism.

Pieter also recently attended BIO in Washington DC and produced a short video report about the meeting:

Following a trip to Boston & Cambridge, Pieter produced a short video about what makes this the top biotech region on the East Coast of the United States:

At the recent 2011 European Multidisciplinary Cancer Congress (ECCO ESMO ESTRO 2011), Pieter produced a video of the radium-223 (Alpharadin) media briefing, where the ALSYMPCA phase 3 prostate cancer trial data was presented.

Pieter, subsequently interviewed Dr Chris Parker (The Royal Marsden Hospital) about the ALSYMPCA data presented at the Congress and discussed some of the challenges and opportunities for radium-223 (Alpharadin) in advanced prostate cancer.